ONCY — Oncolytics Biotech Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Oncolytics Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 32.7 | 23.7 | 26.4 | 11.1 | 5.2 |
| Net Total Receivables | 0.685 | 0.385 | 0.011 | 0.047 | 0.573 |
| Prepaid Expenses | |||||
| Total Current Assets | 35.5 | 26.3 | 28.8 | 12.4 | 6.84 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.773 | 0.481 | 0.488 | 0.985 | 0.738 |
| Other Long Term Assets | |||||
| Total Assets | 36.3 | 27.6 | 29.3 | 13.4 | 7.58 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.13 | 2.91 | 2.38 | 4.88 | 6.1 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.74 | 7.99 | 8.5 | 10.1 | 11.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 28.6 | 19.6 | 20.8 | 3.3 | -3.8 |
| Total Liabilities & Shareholders' Equity | 36.3 | 27.6 | 29.3 | 13.4 | 7.58 |
| Total Common Shares Outstanding |